Improved Survival in HIV-Associated Diffuse Large B-Cell Lymphoma with the Addition of Rituximab to Chemotherapy in Patients Receiving Highly Active Antiretroviral Therapy

REFERENCES

• Kaplan LD, Straus DJ, Testa MA, et al. Low-dose com-pared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immu-nodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Eng' J Med. 1997;336(23):1641–1648.
   PubMed Web of Science ®Google Scholar
• Dal Maso L, Clifford G, Polesel J, Franceschi S, Ricken-bach M. Effect of individual HAART treatment on Hodgkin and non-Hodgkin lymphoma risk among HIV patients. Ann Oncol. 2005;16\(Suppl 5):v28a.
   Google Scholar
• Cortes J, Thomas D, Rios A, et al. Hyperfractionated cy-clophosphamide, vincristine, doxorubicin, and dexameth-asone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 2002 ;94(5):1492–1499.
   PubMed Web of Science ®Google Scholar
• Krishnan A, Molina A, Zaia J, et al. Autologous stem cell transplantation for HIV-associated lymphoma. Blood. 2001;98(13):3857–3859.
   PubMed Web of Science ®Google Scholar
• Lim ST, Karim R, Nathwani BN, Tulpule A, Espina B, Levine AM. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol. 2005;23(19):4430–4438.
   PubMed Web of Science ®Google Scholar
• Weiss R, Mitrou P, Arasteh K, Schurmann D, Huhn D. HIV-related lymphoma: changes in immune parameters and viral load during chemotherapy. Blood. 2000;96(11):134a.
   Web of Science ®Google Scholar
• Antinori A, Cingolani A, Alba L, et al. Better response to chemotherapy and prolonged survival in AIDS-related lym-phomas responding to highly active antiretroviral therapy. AIDS. 200115(12):1483–1491.
   Web of Science ®Google Scholar
• Besson C, Goubar A, Gabarre J, et al. Changes in AIDS-related lymphoma since the era of highly active antiretrovi-ral therapy. Blood. 2001;98(8):2339–2344.
   PubMed Web of Science ®Google Scholar
• Chow KU, Mitrou PS, Geduldig K, Helm EB, Hoelzer D, Brodt HR. Changing incidence and survival in patients with AIDS-related non-Hodgkin's lymphomas in the era of highly active antiretroviral therapy (HAART). Leukemia Lymphoma. 200141(1–2): 105-116.
   Web of Science ®Google Scholar
• Kirk O, Pedersen C, Cozzi-Lepri A, et al. Non-Hodgkin lym-phoma in HIV-infected patients in the era of highly active antiretroviral therapy [comment]. Blood. 200198(12):3406–3412.
   Web of Science ®Google Scholar
• Matthews GV, Bower M, Mandelia S, Powles T, Nelson MR, Gazzard BG. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood. 2000;96(8):2730–2734.
   PubMed Web of Science ®Google Scholar
• Navarro JT, Ribera JM, Oriol A, Tura! C, Mille F, Feliu E. Improved outcome of AIDS-related lymphoma in patients with virologic response to highly active antiretroviral ther-apy. J Acquir Immune Defic Syndr 2003;32(3):347–348.
   PubMed Web of Science ®Google Scholar
• Vaccher E, di Gennaro G, Shioppa O, et al. Highly active antiretroviral therapy (HAART) significantly improves dis-ease free survival (DFS) in patients (pts) with HIV-related non-Hodgkin's lymphoma (HIV-NHL) treated with chemo-therapy (CT). Proc ASCO. 2001;20(2):294a.
   Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly pa-tients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–242.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically im-proved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23(22):5027–5033.
   PubMed Web of Science ®Google Scholar
• Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005;106(5):1538–1543.
   PubMed Web of Science ®Google Scholar
• Sparano JA, Lee S, Chen MG, et al. Phase ll trial of infu-sional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494). J Clin Oncol. 2004;22(8)1491–1500.
   Web of Science ®Google Scholar
• Spina M, Jaeger U, Sparano JA, et al. Rituximab plus in-fusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood. 2005;105(5):1891–1897.
   PubMed Web of Science ®Google Scholar
• Spina M, Vaccher E, Juzbasic S, et al. Human immuno-deficiency virus-related non-Hodgkin lymphoma: activity of infusional cyclophosphamide, doxorubicin, and etopo-side as second-line chemotherapy in 40 patients. Cancer 2001;92(1):200–206.
   PubMed Web of Science ®Google Scholar
• Gatter KC, Warmke RA. Diffuse large B-cell lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, PA: IARC Press; 2001:171–174.
   Google Scholar
• Hoskins PJ, Le N, Gascoyne RD, et al. Advanced diffuse large-cell lymphoma treated with 12-week combination chemotherapy: natural history of relapse after initial complete response and prognostic variables defining outcome after relapse. Ann Oncol. 1997;8(11):1125–1132.
   PubMed Web of Science ®Google Scholar
• O'Reilly SE, Hoskins P, Klimo P, Connors JM. MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ ABV in Hodgkin's disease. Ann Oncol. 1991;2\(Suppl 1):17–23.
   PubMed Web of Science ®Google Scholar
• Carpenter CC, Fisch! MA, Hammer SM, et al. Antiretrovi-ral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA. 1996;276(2):146–154.
   PubMed Web of Science ®Google Scholar
• Rossi G, Donisi A, Casari S, Re A, Cadeo G, Carosi G. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human im-munodeficiency virus-related systemic non-Hodgkin lym-phoma. Cancer 1999.86(11):2391–2397.
   PubMed Web of Science ®Google Scholar
• Bower M, Gazzard B, Mandalia S, et al. A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. Ann Intern Med. 2005;143(4):265–273.
   PubMed Web of Science ®Google Scholar
• Kaplan LD, Lee J, Scadden DT. No benefit from rituximab in a randomized phase III trial of CHOP with or without rituximab for patients with HIV-associated non-Hodgkin's lymphoma: updated data from AIDS malignancies consor-tium study 010. Blood. 2003;102(11):409–410a.
   Web of Science ®Google Scholar
• Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemo-therapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328(14):1002–1006.
   PubMed Web of Science ®Google Scholar
• Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regi-men. J Clin Oncol. 1996;14(3):925–934.
   PubMed Web of Science ®Google Scholar
• Boue F, Gabarre J, Gisselbrecht C, et al. Phase ll trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol. 2006;24(25):4123–4128.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller E, Morrison VA, et al. Rituximab-CHOP versus CHOP with or without maintenance rituximab in patients 60 years of age or older with diffuse large B-cell lymphoma (DLBCL): an update. Blood. 2004;104(11):40a.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Wilson WH, Kaplan LD. The case for ritux-imab in AIDS-related lymphoma. Blood. 2006;107(7):3014–3015.
   PubMed Web of Science ®Google Scholar
• Ledergerber B, Egger M, Erard V, et al. AIDS-related op-portunistic illnesses occurring after initiation of potent anti-retroviral therapy: the Swiss HIV Cohort Study [comment]. JAMA. 1999;282(23):2220–2226.
   PubMed Web of Science ®Google Scholar
• Weir A, Wansbrough-Jones M. Mucosa! Kaposi's sarcoma following protease inhibitor therapy in an HIV-infected pa-tient. AIDS. 1997;11(15):1895–1896.
   PubMed Web of Science ®Google Scholar
• Chaiwatanatorn K, Lee N, Grigg A, Filshie R, Firkin F. Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol. 2003;121(6):913–918.
   PubMed Web of Science ®Google Scholar
• Motl SE, Baskin RC. Delayed-onset grade 4 neutropenia associated with rituximab therapy in a patient with lym-phoma: case report and literature review. Pharmacother-apy. 2005;25(8):1151–1155.
   PubMed Web of Science ®Google Scholar